<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01006941</url>
  </required_header>
  <id_info>
    <org_study_id>Rigshospitalet, DMSC</org_study_id>
    <nct_id>NCT01006941</nct_id>
  </id_info>
  <brief_title>Trichuris Suis Ova Therapy for Relapsing Multiple Sclerosis - a Safety Study</brief_title>
  <acronym>TRIMS A</acronym>
  <official_title>Trichuris Suis Ova Therapy for Relapsing Multiple Sclerosis - a Safety Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Statens Serum Institut</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Copenhagen University Hospital, Hvidovre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>OvaMed GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis of this study is that treatment with Trichuris suis ova will be safe and&#xD;
      effective as an oral treatment of patients with relapsing multiple sclerosis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MRI activity judged by the number of new or enlarging T2 lesions, number of Gd enhancing lesions and volume of T2 lesions</measure>
    <time_frame>every 3. week. 3 MRI before treatment and 4 MRI during and after treatment</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Relapsing Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Trichuris suis ova</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Trichuris suis ova</intervention_name>
    <description>2500 ova per dose, orally, every second week, during 12 weeks</description>
    <arm_group_label>Trichuris suis ova</arm_group_label>
    <other_name>TSO</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age between 19 and 55 years&#xD;
&#xD;
          -  relapsing course of multiple sclerosis (relapsing-remitting or secondary progressive&#xD;
             MS with relapses&#xD;
&#xD;
          -  duration of the disease of at least 1 year&#xD;
&#xD;
          -  no disease modifying therapy or unchanged immunomodulatory therapy for the last 3&#xD;
             months&#xD;
&#xD;
          -  at least 2 documented relapses during the last 24 months with the last relapse within&#xD;
             the last 12 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnancy or period of breastfeeding or missing adequate contraceptive protection for&#xD;
             female premenopausal patients&#xD;
&#xD;
          -  relapse in the last month prior enrolment&#xD;
&#xD;
          -  treatment with steroids in the last 30 days&#xD;
&#xD;
          -  previous treatment with mitoxantroneduring the last year&#xD;
&#xD;
          -  previous treatment with cyclophosphamide or other intensive immunosuppression, total&#xD;
             irradiation&#xD;
&#xD;
          -  treatment with glatiramer acetate, azathioprine, IVIG or any other immunosuppressive&#xD;
             or immunomodulatory drug apart from interferon-beta in the 6 months prior to enrolment&#xD;
&#xD;
          -  cardiac insufficiency (NYHA III/IV), cardiomyopathy, significant cardiac dysrhythmia&#xD;
             requiring treatment, instable or advanced ischemic heart disease (CCS III or IV),&#xD;
             malignant hypertension&#xD;
&#xD;
          -  diabetes mellitus and other autoimmune diseases&#xD;
&#xD;
          -  history of renal insufficiency&#xD;
&#xD;
          -  stay in tropical areas during the last 3 months&#xD;
&#xD;
          -  eosinophilia in the blood (&gt; 0,45 billion/l)&#xD;
&#xD;
          -  concurrent systemic infections&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Per S SÃ¸rensen, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Rigshospitalet, Danish Multiple Slerosis Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Danish Multiple Sclerosis Center, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <study_first_submitted>October 7, 2009</study_first_submitted>
  <study_first_submitted_qc>November 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2009</study_first_posted>
  <last_update_submitted>November 9, 2011</last_update_submitted>
  <last_update_submitted_qc>November 9, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 10, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Ana Voldsgaard</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Multiple sclerosis</keyword>
  <keyword>safety</keyword>
  <keyword>MRI</keyword>
  <keyword>immunological</keyword>
  <keyword>Helminths</keyword>
  <keyword>Trichuris suis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

